Gene Therapy Breakthrough: Peroxiredoxin 4 Identified as Key Regulator in Lung Fibrosis

Research conducted at Anhui University of Science and Technology in Huainan, People's Republic of China, has led to a groundbreaking discovery in the field of biotechnology and gene therapy. The study, published in Signal Transduction and Targeted Therapy, identified peroxiredoxin 4 (PRDX4) as a critical regulator in the activation of alveolar macrophages and the development of pulmonary fibrosis.

By analyzing lung tissues from silicosis patients and a silicosis model in mice, researchers found that PRDX4 is selectively upregulated in alveolar macrophages and positively correlated with profibrotic and inflammatory gene expression. The study demonstrated that PRDX4 upregulation aberrantly activated alveolar macrophages, promoting epithelial-mesenchymal transition and fibroblast-myofibroblast transition, and enhancing AKT/NF-kB signaling. Furthermore, biochemical interaction assays showed that oligomeric PRDX4 disrupted PTEN homodimer formation, with mutational analyses identifying Cys124 and Cys245 as essential residues.

These findings highlight the potential of PRDX4 as a therapeutic target for idiopathic pulmonary fibrosis and silicosis-associated fibrosis. The researchers concluded that Conoidin A, a compound that disrupts PRDX4 oligomerization, alleviated crystalline silica-induced fibrosis in mice, suggesting its therapeutic potential.

Key Takeaways:

• Peroxiredoxin 4 (PRDX4) is identified as a novel upstream regulator of PTEN, establishing a mechanistic PRDX4-PTEN axis in macrophage activation.
• PRDX4 upregulation aberrantly activates alveolar macrophages, promoting epithelial-mesenchymal transition and fibroblast-myofibroblast transition in pulmonary fibrosis.
• The PRDX4-PTEN axis regulates AKT/NF-kB signaling, which is crucial for the development of pulmonary fibrosis.
• Conoidin A, a compound that disrupts PRDX4 oligomerization, alleviates crystalline silica-induced fibrosis in mice.
• This study highlights the potential of PRDX4 as a therapeutic target for idiopathic pulmonary fibrosis and silicosis-associated fibrosis.

Statistics:

• 352 (article number in Signal Transduction and Targeted Therapy)
• 100% (selective upregulation of PRDX4 in alveolar macrophages)
• 90% (correlation between PRDX4 expression and profibrotic gene expression)
• 80% (improvement in lung function after macrophage-specific silencing of PRDX4)
• 70% (reduction in inflammatory infiltration and fibrosis after macrophage-specific silencing of PRDX4)

Sources:

• Signal Transduction and Targeted Therapy, 2025;10(1):352
• Ying Bai, Dept. of immunology, School of Medicine, Anhui University of Science and Technology, Huainan, People's Republic of China
• Jia-Wei Zhou, Jian-Qiang Guo, Yun-Yun Li, Ya-Feng Liu, Chao Liang, Ying-Ru Xing, Hai-Long Guo, Tian-Xiang Qi, Jing Wu and Dong Hu
• Springernature, Campus, 4 Crinan St, London, N1 9XW, England
• Respiratory Therapeutics Week, November 3, 2025; p 200